S&P 500   3,341.97 (+1.32%)
DOW   27,602.63 (+1.58%)
QQQ   274.69 (+1.15%)
AAPL   113.20 (+0.82%)
MSFT   208.50 (+0.33%)
FB   255.48 (+0.26%)
GOOGL   1,455.45 (+1.14%)
AMZN   3,140.09 (+1.45%)
TSLA   420.10 (+3.13%)
NVDA   513.74 (-0.23%)
BABA   275.54 (+1.64%)
CGC   14.07 (-0.71%)
GE   6.27 (+2.62%)
MU   49.53 (+0.79%)
AMD   78.78 (+0.92%)
T   28.34 (+1.07%)
F   6.68 (+2.61%)
ACB   4.82 (-4.55%)
GILD   62.91 (+1.06%)
NFLX   481.65 (-0.25%)
DIS   125.74 (+1.40%)
BAC   24.12 (+2.68%)
BA   163.60 (+4.85%)
S&P 500   3,341.97 (+1.32%)
DOW   27,602.63 (+1.58%)
QQQ   274.69 (+1.15%)
AAPL   113.20 (+0.82%)
MSFT   208.50 (+0.33%)
FB   255.48 (+0.26%)
GOOGL   1,455.45 (+1.14%)
AMZN   3,140.09 (+1.45%)
TSLA   420.10 (+3.13%)
NVDA   513.74 (-0.23%)
BABA   275.54 (+1.64%)
CGC   14.07 (-0.71%)
GE   6.27 (+2.62%)
MU   49.53 (+0.79%)
AMD   78.78 (+0.92%)
T   28.34 (+1.07%)
F   6.68 (+2.61%)
ACB   4.82 (-4.55%)
GILD   62.91 (+1.06%)
NFLX   481.65 (-0.25%)
DIS   125.74 (+1.40%)
BAC   24.12 (+2.68%)
BA   163.60 (+4.85%)
S&P 500   3,341.97 (+1.32%)
DOW   27,602.63 (+1.58%)
QQQ   274.69 (+1.15%)
AAPL   113.20 (+0.82%)
MSFT   208.50 (+0.33%)
FB   255.48 (+0.26%)
GOOGL   1,455.45 (+1.14%)
AMZN   3,140.09 (+1.45%)
TSLA   420.10 (+3.13%)
NVDA   513.74 (-0.23%)
BABA   275.54 (+1.64%)
CGC   14.07 (-0.71%)
GE   6.27 (+2.62%)
MU   49.53 (+0.79%)
AMD   78.78 (+0.92%)
T   28.34 (+1.07%)
F   6.68 (+2.61%)
ACB   4.82 (-4.55%)
GILD   62.91 (+1.06%)
NFLX   481.65 (-0.25%)
DIS   125.74 (+1.40%)
BAC   24.12 (+2.68%)
BA   163.60 (+4.85%)
S&P 500   3,341.97 (+1.32%)
DOW   27,602.63 (+1.58%)
QQQ   274.69 (+1.15%)
AAPL   113.20 (+0.82%)
MSFT   208.50 (+0.33%)
FB   255.48 (+0.26%)
GOOGL   1,455.45 (+1.14%)
AMZN   3,140.09 (+1.45%)
TSLA   420.10 (+3.13%)
NVDA   513.74 (-0.23%)
BABA   275.54 (+1.64%)
CGC   14.07 (-0.71%)
GE   6.27 (+2.62%)
MU   49.53 (+0.79%)
AMD   78.78 (+0.92%)
T   28.34 (+1.07%)
F   6.68 (+2.61%)
ACB   4.82 (-4.55%)
GILD   62.91 (+1.06%)
NFLX   481.65 (-0.25%)
DIS   125.74 (+1.40%)
BAC   24.12 (+2.68%)
BA   163.60 (+4.85%)
Log in
NYSEAMERICAN:IBIO

Ibio Stock Forecast, Price & News

$2.01
-0.07 (-3.37 %)
(As of 09/28/2020 10:42 AM ET)
Add
Compare
Today's Range
$1.97
Now: $2.01
$2.19
50-Day Range N/A
52-Week Range
$0.05
Now: $2.01
$7.45
Volume251,017 shs
Average Volume25.10 million shs
Market Capitalization$350.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:IBIO
Previous SymbolNASDAQ:IBIO
CUSIPN/A
Phone+1-302-3550650

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees54
Market Cap$350.57 million
Next Earnings Date10/2/2020 (Estimated)
OptionableNot Optionable
$2.01
-0.07 (-3.37 %)
(As of 09/28/2020 10:42 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Ibio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ibio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ibio
.

When is Ibio's next earnings date?

Ibio is scheduled to release its next quarterly earnings announcement on Friday, October 2nd 2020.
View our earnings forecast for Ibio
.

When did Ibio's stock split? How did Ibio's stock split work?

Ibio's stock reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

1 analysts have issued 12-month price objectives for Ibio's stock. Their forecasts range from $2.55 to $2.55. On average, they anticipate Ibio's share price to reach $2.55 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price.
View analysts' price targets for Ibio
.

Are investors shorting Ibio?

Ibio saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 20,000,000 shares, an increase of 24.8% from the August 31st total of 16,020,000 shares. Based on an average daily volume of 35,280,000 shares, the days-to-cover ratio is presently 0.6 days.
View Ibio's Short Interest
.

Who are some of Ibio's key competitors?

What other stocks do shareholders of Ibio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Heat Biologics (HTBX), Dynavax Technologies (DVAX), Novavax (NVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

Who are Ibio's key executives?

Ibio's management team includes the following people:
  • Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)
  • Mr. Robert L. Erwin, Pres (Age 66)
  • Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)
  • Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)
  • Dr. Renato Lobo, Chief Medical Officer

What is Ibio's stock symbol?

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are Ibio's major shareholders?

Ibio's stock is owned by a number of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.27%), Nuveen Asset Management LLC (0.16%), Bank of New York Mellon Corp (0.13%), Charles Schwab Investment Management Inc. (0.12%), Goldman Sachs Group Inc. (0.06%) and New York State Common Retirement Fund (0.05%). Company insiders that own Ibio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for Ibio
.

Which major investors are selling Ibio stock?

IBIO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Ibio company stock in the last year include Eastern Capital Ltd, James P Mullaney, and Robert L Erwin.
View insider buying and selling activity for Ibio
.

Which major investors are buying Ibio stock?

IBIO stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Jane Street Group LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, New York State Common Retirement Fund, National Asset Management Inc., Virtu Financial LLC, and Harvey Capital Management Inc..
View insider buying and selling activity for Ibio
.

How do I buy shares of Ibio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ibio's stock price today?

One share of IBIO stock can currently be purchased for approximately $2.00.

How big of a company is Ibio?

Ibio has a market capitalization of $348.83 million. Ibio employs 54 workers across the globe.

What is Ibio's official website?

The official website for Ibio is www.ibioinc.com.

How can I contact Ibio?

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.